Maximize your biologically actionable insights from small tumor samples with the SOPHiA DDM™ RNAtarget Technology end-to-end solutions
Gene fusions have been associated with various tumors and are recognized as valuable cancer biomarkers in cancer research1. Targeted RNA sequencing is recommended to maximize novel fusion detection by identifying transcribed and potentially actionable fusions.
RNA sequencing fusion detection has become an integral tool of cancer research, as it allows clinical researchers to identify genetic abnormalities that trigger oncogenesis and progression.
High-performance novel fusion detection
Optimized for small FFPE samples using 10ng of RNA or tNA minimum input
Customizable gene content and full Set Up Program
Streamlined 1.5-day end-to-end workflow, automation-friendly
Detect and interpret novel fusions, SNVs, and Indels in major lung cancer biomarkers (45 relevant genes)
Streamlined visualization , filtering and reporting with the SOPHiA DDM™ Platform
SOPHiA DDM™ RNAtarget Technology
Unleash the capabilities of RNA Sequencing and expand your cancer research insights using SOPHiA GENETICS’s end-to-end applications for small tumor samples
Choose the solution that fits your needs
Our comprehensive portfolio offers ready-to-use and customizable solutions based on RNAtarget Technology features and performances
SOPHiA DDM™️ RNAtarget Oncology Solution
SOPHiA DDM™️ RNAtarget Oncology Solution is a comprehensive application that covers 45 genes relevant for solid tumors, with a focus on lung cancer.
SOPHiA DDM™️ Dx RNAtarget Oncology Solution
SOPHiA DDM™️ Dx RNAtarget Oncology Solution is also available as a CE-IVD product, enabling novel fusion detection in small samples to improve lung cancer management. Read More
SOPHiA GENETICS™ Community Panels
SOPHiA GENETICS™ Community Panels are targeted panels developed and tested by genomic experts of their fields to minimize set-up challenges and accelerate your workflow.
Custom Applications
SOPHiA GENETICS™ Custom applications are panels specifically designed at your request to analyze genes relevant to your laboratory.
SOPHiA DDM™ RNAtarget Technology Workflow
SOPHiA DDM™️ RNAtarget Oncology Solution Features
SOPHiA DDM™ RNAtarget Oncology Solution covers 45 genes associated with solid tumors, with a focus on lung cancer biomarkers. Our technology offers novel (partner-agnostic) fusion detection combined with the ability to detect SNVs/Indels and unlock the capacity to assess expression changes. Probe design is optimized to guarantee high on-target rate and coverage uniformity even in GC-rich regions. For specific needs, the gene content can be fully customized.
Minimal RNA/tNA input amount required
Comprehensive variants detection, visualization and filtering
Direct access to the latest scientific evidence via OncoPortal™ Plus
Intuitive and fully automated reporting
Benefit from sensitive novel fusion detection
SOPHiA DDM™ RNAtarget Technology matches technical sensitivity of a fully-guided amplicon-based solution while detecting more fusions due to novel fusion detection capability.
Detect more with less
RNAtarget Technology detects more fusions in minimal input material (20ng) compared to a standard amplicon-based solution with novel fusion detection capabilities.
Secondary and tertiary analysis powered by SOPHiA DDM™️ Platform
Specifications
Parameters |
SOPHiA DDM™ RNAtarget Technology |
| Sample Type |
FFPE, fresh frozen tissue |
| Input Type | RNA or tNA |
| Input Amount | 10-200 ng, 50 ng recommended |
| Sequencer Compatibility |
|
| Library Preparation Time | 1.5 days |
| Analysis Time From FASTQ File | 8h/16 sample batch |
| Detected Variants |
|
*The parameters are not applicable for SOPHiA DDM™️ Dx RNAtarget Oncology Solution
SOPHiA DDM™️ RNAtarget Oncology Solution
Major lung cancer biomarkers
EGFR (vIII exon skipping), KRAS (G12C), ALK, ROS1, BRAF (V600E), NTRK, MET (exon 14 skipping), RET, ERB2 and PD-L1
Specifications
- Panel size: 97kb
- Mixed exon/full gene coverage
- Pipelines for Illumina NextSeq® and MiSeq®
Resources
Webinars
Related Blog
Want to know more?
Get in touch with us.
Our client services team is on hand to help.